These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28950425)

  • 1. Pulmonary presentation of Kawasaki disease-A diagnostic challenge.
    Singh S; Gupta A; Jindal AK; Gupta A; Suri D; Rawat A; Vaidya PC; Singh M
    Pediatr Pulmonol; 2018 Jan; 53(1):103-107. PubMed ID: 28950425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Kawasaki disease at a tertiary care center in Chandigarh, North West India: 24 years of clinical experience.
    Guleria S; Pilania RK; Jindal AK; Bhattarai D; Suri D; Singh S
    Int J Rheum Dis; 2019 Jul; 22(7):1183-1187. PubMed ID: 30829007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
    Singh S; Sharma D; Suri D; Gupta A; Rawat A; Rohit MK
    Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective follow-up cardiac evaluation of children with Kawasaki disease in Northern India using the Japanese echocardiography criteria.
    Kothur K; Singh S; Sharma Y; Mittal BR
    J Cardiol; 2007 Nov; 50(5):299-307. PubMed ID: 18044459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kawasaki disease presenting with hemorrhagic pleural effusion.
    D'Souza S; Khubchandani RP; Shetty AK
    J Trop Pediatr; 2006 Aug; 52(4):299-301. PubMed ID: 16188905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kawasaki disease in infants below 6 months: a clinical conundrum?
    Singh S; Agarwal S; Bhattad S; Gupta A; Suri D; Rawat A; Singhal M; Rohit M
    Int J Rheum Dis; 2016 Sep; 19(9):924-8. PubMed ID: 26990891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic predominant presentation of Kawasaki disease in adolescence case report and review of literature.
    Pratap K; Gardner LS; Gillis D; Newman M; Wainwright D; Prentice R
    BMC Gastroenterol; 2020 Oct; 20(1):352. PubMed ID: 33109118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of the course, treatment and long-term follow-up of Kawasaki disease: a single-center experience from Poland.
    Stasiak A; Smolewska E
    Rheumatol Int; 2019 Jun; 39(6):1069-1076. PubMed ID: 30903369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):501.e1-11; quiz 511-2. PubMed ID: 24034379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case report of atypical Kawasaki disease presented with severe elevated transaminases and literature review.
    Ren Y; Zhang C; Xu X; Yin Y
    BMC Infect Dis; 2021 May; 21(1):415. PubMed ID: 33947336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varying clinical features of Turkish Kawasaki disease patients.
    Gülhan B; Kesici S; Beken S; Cilsal E; Kale G; Alehan D; Kara A; Ozen S
    Turk J Pediatr; 2012; 54(1):1-6. PubMed ID: 22397034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kawasaki disease malingering as juvenile dermatomyositis: case-based review : Myositis in Kawasaki disease.
    Anjani G; Johnson N; Navid A; Saka R; Jindal AK; Singh S
    Rheumatol Int; 2022 May; 42(5):913-919. PubMed ID: 33682025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
    Kubota M; Usami I; Yamakawa M; Tomita Y; Haruta T
    J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifteen-minute consultation: Kawasaki disease: how to distinguish from other febrile illnesses: tricks and tips.
    Kelly A; Sales K; Fenton-Jones M; Tulloh R
    Arch Dis Child Educ Pract Ed; 2020 Jun; 105(3):152-156. PubMed ID: 31900257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kawasaki disease in children and adolescents: clinical data of Kawasaki patients in a western region (Tyrol) of Austria from 2003-2012.
    Binder E; Griesmaier E; Giner T; Sailer-Höck M; Brunner J
    Pediatr Rheumatol Online J; 2014 Sep; 12(1):37. PubMed ID: 27643389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has joint involvement lessened in Kawasaki disease?
    Álvarez EP; Rey F; Peña SC; Rubio A; Calvo C; Collado P
    Reumatol Clin; 2017; 13(3):145-149. PubMed ID: 27263965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.